| Role of CBD in Regulating Meal Time Anxiety in Anorexia Nervosa | The Role of Cannabidiol in Regulating Meal Time Anxiety in Anorexia Nervous: Safety, Tolerability and Pharmacokinetics | NCT04878627 |
| The Effects of Cannabidiol and Homotaurine in Patients With Mild Cognitive Impairment | Comparative Randomized Clinical Trial of the Efficacy of Cannabidiol and Homotaurine in Patients With Mild Cognitive Impairment and APOE e4 Carriers | NCT05022186 |
| Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder | A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study, Evaluating the Efficacy, Safety, and Tolerability of Cannabidiol Oral Solution in Subjects With Social Anxiety Disorder | NCT05600114 |
| Clinical Study to Evaluate Cannabidiol Liver Enzyme Elevations and Drug Interactions | Clinical Study to Evaluate Cannabidiol Liver Enzyme Elevations and Drug Interactions | NCT06192589 |
| Alcohol Use Disorder and Cannabidiol | Alcohol Use Disorder and Cannabis: Testing Novel Harm Reduction Strategies | NCT05613608 |
| Evaluation of the Interactions of Cannabidiol (CBD) With Morphine | Phase 1 Drug-drug Interaction of Cannabidiol and Morphine in Recreational Opioid Users | NCT05143424 |
| Therapeutic Response of Cannabidiol in Rheumatoid Arthritis | Randomized, Double Blind, Placebo-Controlled Trial to Evaluate the Safety and Tolerability of Cannabidiol (CBD) in Moderate to Severe Rheumatoid Arthritis | NCT04911127 |
| Evaluation of the effect of cannabidiol in the treatment of dystonia | Evaluation of the effect of cannabidiol in the treatment of adult dystonias-a randomized placebo-controlled clinical trial | IRCT20211019052811N1 |
| Cannabidiol (CBD) in Adults With ASD | Crossover Trial of Cannabidiol (CBD) Versus Placebo for Psychiatric Presentations in Adults With Autism Spectrum Disorder | NCT05015439 |
| Evaluation of Effects of CBD Products on Anxiety Among U.S. Women | A Retrospective Cohort Study to Evaluate the Effects of Cannabidiol (CBD)-Containing Test Products on Anxiety Among Women in the U.S. | NCT05108220 |
| Cannabidiol in Restless Leg Syndrome | Comparison of the effectiveness of Cannabidiol drop with Pramipexole in Restless Leg Syndrome severity index - randomized parallel clinical trial | IRCT20210901052359N1 |
| The Effects of Cannabidiol (CBD) on Affective and Physiological Responses to Exercise in Healthy Endurance-Trained Runners | The Acute Effects of Cannabidiol on Affective and Physiological Responses to Exercise in Healthy Endurance-Trained Runners: A Randomised, Double-blind, Placebo-controlled, Dose-ranging, Crossover Trial | ACTRN12622000717752 |
| CBD for Sleep in People With HIV | Pilot Trial of Cannabidiol (CBD) for Sleep Problems in People With HIV | NCT05097651 |
| The Efficacy and Neurobehavioural Mechanism of Cannabidiol (CBD) for Alcohol Dependence | The Efficacy and Neurobehavioural Mechanism of Cannabidiol (CBD) for Alcohol Dependence: An Exploratory Pilot Study | NCT05387148 |
| Effects of cannabidiol (CBD) on chronic pain following spinal cord injury | A randomised, double-blind, placebo-controlled, cross-over, pilot trial exploring the effects of cannabidiol (CBD) on chronic pain following spinal cord injury | ACTRN12622000634774 |
| Cannabidiol: Treatment for brain changes and depression in early-stage dementia | Cannabidiol: Treatment for brain changes and depression in early-stage dementia | ACTRN12621001364864 |
| A Study of RAD011 (Cannabidiol Oral Solution) for the Treatment of Patients with Prader-Willi Syndrome | A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of RAD011 (Cannabidiol Oral Solution) for the Treatment of Patients with Prader-Willi Syndrome | EUCTR2021-005331-23-ES |
| Oral Cannabidiol Effect on Blood Pressure in Hypertensive Patients | Chronic Effects of Effective Oral Cannabidiol Delivery on 24-hour Ambulatory Blood Pressure and Vascular Outcomes in Treated and Untreated Hypertension: A Randomized, Placebo-controlled and Crossover Study | NCT05346562 |
| Cannabidiol in Youth Alcohol Use Disorder | Neurobehavioral Effects of Cannabidiol in Youth Alcohol Use Disorder | NCT05317546 |
| Effects of cannabidiol in children with autism | A randomised crossover trial examining behavioural and neurophysiological effects of cannabidiol (CBD) in children with autism | ACTRN12622000437763 |
| Influence of Cannabidiol on Glucose Tolerance and The Gut Microbiota | Influence of Cannabidiol on Glucose Tolerance and The Gut Microbiota | NCT05285449 |
| A Single Centre Observational Study to Assess whether a Topically Applied Cannabidiol Gel can Reduce Symptoms of Painful Osteoarthritis of the Hand | A Single Centre Observational Study to Assess whether a Topically Applied Cannabidiol Gel can Reduce Pain, Increase Grip Strength, or Improve Joint Functionality for Sufferers of Painful Osteoarthritis of the Hand | ACTRN12621001512819 |
| Safety and Efficacy of Cannabidiol (CBD) for Symptoms of PTSD in Adults | Safety and Efficacy of Cannabidiol (CBD) for Symptoms of Post-Traumatic Stress Disorder (PTSD) in Adults Using Liquid StructureTM Formulation (NantheiaTM ATL5). | NCT05269459 |
| Cannabidiol Effects on Learning and Anxiety | Cannabidiol Effects on Learning and Anxiety | NCT05283382 |
| Use of Cannabidiol in Patients with Chronic Heart Failure | Cannabidiol in Patients with Chronic Heart Failure: a prospective, randomized, double-blind, controlled trial | RBR-9z6dw6b |
| Investigation of the Pharmacokinetic Profile of CBD | Cannabidiol in the Treatment of Opioid Use Disorder | NCT05269706 |
| Effectiveness of Cannabidiol Vs. Narcotics for Post Operative Pain Control in Elective Shoulder Arthroscopic Surgery | Effectiveness of Cannabidiol Vs. Narcotics for Post Operative Pain Control in Elective Shoulder Arthroscopic Surgery | NCT05240755 |
| Cannabidiol Effects on Cardiovascular System and Exercise Responses | Cannabidiol Effects on Cardiovascular System and Exercise Responses | NCT05232123 |
| A pilot randomised controlled trial testing the efficacy of cannabidiol for anxiety in Tourette Syndrome | A pilot randomised controlled trial testing the efficacy of cannabidiol for anxiety in Tourette Syndrome | ACTRN12621001659897 |
| Cannabidiol for Reducing Drinking in Alcohol Use Disorder | Cannabidiol for Reducing Drinking in Alcohol Use Disorder and Modifying the Effects of Alcohol on the Brain and the Liver: a Phase 2 Clinical Trial.-The CARAMEL Study | NCT05159830 |
| Cannabidiol use in women with endometriosis and chronic pelvic pain: evaluation in pain and quality of life | Cannabidiol use in women with endometriosis and chronic pelvic pain: a randomized duble-blind clinical trial for evaluation in pan and quality of life | RBR-6ryrpjs |
| Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy | Topical Cannabidiol (CBD) for the Treatment of Chemotherapy-Induced Peripheral Neuropathy: A Randomized Placebo-Controlled Pilot Trial | NCT05388058 |
| Efficacy and Safety of Cannabidiol Oil in Psoriasis: A Randomized, Double-Blind, Placebo-Controlled Trial | Efficacy and Safety of Cannabidiol Oil in Psoriasis: A Randomized, Double-Blind, Placebo-Controlled Trial | TCTR20220622002 |
| Canabidiol (CBD) for Treatment of Frontal Lobe Epilepsy | Efficacy of Cannabidiol (CBD) in Patients with Treatment-Resistant Frontal Lobe Epilepsy | IRCT20210608051515N1 |
| Cannabidiol on Reward- and Stress-related Neurocognitive Processes in Individuals With Opioid Use Disorder | Cannabidiol on reward-and Stress-related Neurocognitive Processes in Individuals With Opioid Use Disorder: A Double-blind, Placebo-controlled, Cross-over Trial | NCT04982029 |
| Clinical study of cannabidiol in children, adolescents and young adults with Fragile X syndrome (RECONNECT) | A Randomized, Double-Blind, Placebo-Controlled Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children, Adolescents and Young Adults with Fragile X Syndrome - RECONNECT | ACTRN12621000874819 |
| Cannabidiol (CBD) in Pain Reduction for Knee Osteoarthritis | The Use of Cannabidiol (CBD) in Pain Reduction for Knee Osteoarthritis. A Double-Blind, Randomized Control Study | NCT05020028 |
| Topical Cannabidiol Cream and Post-exercise Recovery | The Effects of Topical Cannabidiol Cream on Post-exercise Recovery | NCT05044936 |
| Enhancing Prolonged Exposure With Cannabidiol to Treat Posttraumatic Stress Disorder | Enhancing Prolonged Exposure With Cannabidiol to Treat Posttraumatic Stress Disorder: A Pilot Study | NCT05132699 |
| Anxiety Symptoms in Relation to Use of Hemp-derived, Full Spectrum Cannabidiol (CBD) | Anxiety Symptoms in Relation to Use of Hemp-Derived, Full Spectrum Cannabidiol (CBD): a Cohort Study | NCT05023759 |
| Pharmacokinetic Study of a Novel Lipid Formulation of Cannabidiol Compared to a Standard Formulation | Pharmacokinetic Study of a Novel Lipid Formulation of Cannabidiol Compared to a Standard Formulation | NCT05032807 |
| Cannabidiol for the Treatment of Anorexia Nervosa (CAFTAN) | Cannabidiol for the Treatment of Anorexia Nervosa (CAFTAN) in 12-65 years old | ACTRN12622001306707 |
| Does taking cannabidiol (CBD) oil with food affect the amount we absorb? | Crossover design pharmacokinetics investigation of Australian Natural Therapeutics Group (ANTG) CBD medium chain triglycerides (MCT) oil with and without fasting in healthy volunteers | ACTRN12622001294741 |
| Cannabidiol as a Treatment for Social Anxiety Disorder (R61) | Randomized Placebo-controlled Trial to Determine the Biological Signature of Cannabidiol as a Treatment for Social Anxiety Disorder (R61) | NCT05571592 |
| Local delivery of cannabidiol in patients with vestibulodynia | Transmucosal delivery of cannabidiol using vestibular electroporation in patients with vestibulodynia: a randomized, blinded prospective trial | ISRCTN74077970 |
| Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution | A Long-term Safety Study to Assess the Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution | NCT05044819 |
| A phase I study to measure the absorption of cannabidiol (CBD) in healthy volunteers after consumption of an oral CBD soft-gel capsule | A Phase I, open label, randomised, single dose, two-way crossover study in healthy volunteers to determine the pharmacokinetics of two doses of an oral cannabidiol soft-gel capsule. | ACTRN12621001181897 |
| Effectiveness of CBD on behavioural problems in patients with TSC, FXS and Sanfilippo | Cannabidiol (Epidyolex) for behavioural problems in patients with Tuberous Sclerosis Complex, Sanfilippo and Fragile X Syndrome: an N-of-1 series - CBD4RARE | EUCTR2021-003250-23-NL |
| Cannabidiol (CBD) for Clozapine Refractory Schizophrenia (CanCloz) | A Multi-Centre Randomised Placebo Controlled Pilot Study of Cannabidiol for Clozapine Refractory Schizophrenia | ACTRN12622001112752 |
| Cannabidiol (MC-1020) Oro-buccal Spray Administration Clinical Trial | Assessing absorption of Cannabidiol (MC-1020) via oro-buccal spray administration in healthy adults | ACTRN12622001034729 |
| Topical Cannabidiol Application and Skin Vascular Reactivity | Cannabidiol and Vascular Reactivity to Skin Sensory Nerve Stimulation | NCT05456113 |
| Oral Cannabidiol for Tobacco Cessation | Oral Cannabidiol for Tobacco Cessation | NCT05445804 |
| Topical application of Cannabis oils and substitutes for the relief of osteoarthritic pain | Phase IIa randomized, placebo-controlled, double-blind crossover pilot study of tolerability and efficacy of cannabidiol (CBD) and palmitoylethanolamide (PEA) applied to the skin for the relief of osteoarthritic joint pain. | ACTRN12622000723785 |
| Assessing the Impact of Cannabidiol for Anxiety and Depression in Bipolar Disorder | Assessing the Impact of Cannabidiol for Anxiety and Depression in Bipolar Disorder | NCT05457465 |
| Cannabidiol enhancement of exposure therapy in treatment refractory patients with phobias. | Cannabidiol enhancement of exposure therapy in treatment refractory patients with phobias. - Cannabidiol in the treatment of phobic anxiety disorders | NL-OMON44760 |
| Investigating the Effects of Cannabidiol on Social Anxiety Disorder | Investigating the Effects of Cannabidiol on Social Anxiety Disorder | NCT05649059 |
| Clinical Trial with Cannabidiol (Kanbis®) for Parkinson Disease Symptoms | Randomized, Double-blind, Placebo-controlled, Phase II Clinical Trial to Evaluate Safety and Tolerability of Cannabidiol (Kanbis®) for the Treatment of Parkinson's Disease Symptoms | NCT06629389 |
| Effects of Cannabidiol on Burnout Syndrome and Empathy of Caregivers of Older Adults | Effects of Cannabidiol on Burnout Syndrome and Empathy of Paid and Unpaid Caregivers of Older Adults | NCT06617247 |
| Trial of Cannabidiol for the treatment of alcohol dependence | Phase II, Placebo-controlled trial of Cannabidiol for the treatment of alcohol dependence (PLACONCANALDE) - PLACONCANALDE | CTIS2023-504439-42-00 |
| A Study of Cannabidiol in Young Adult Cannabis Users | A Randomized, Placebo Controlled Study of Cannabidiol in Young Adult Cannabis Users | NCT06569394 |
| Cannabidiol and Cannabis Concentrate Users | Cannabidiol and Cannabis Concentrate Users: A Randomized, Placebo Controlled Study | NCT06575751 |
| Cannabidiol on beyond-Seizure outcomes in children and adults with Developmental and Epileptic Encephalopathy | A pilot study to investigate the effect of Cannabidiol on quality of life and beyond-seizure outcomes in children and adults with Developmental and Epileptic Encephalopathy | ACTRN12624000888561 |
| Cannabidiol's Role in Dementia Management | Cannabidiol's Role in Dementia Management: Evaluating Cognitive, Quality of Life, and Well-being Outcomes in Malaysia | NCT06514066 |
| Evaluation over time of facial structures in adult patients receiving Treatment for Pain in the Mouth Joint associated with Cannabidiol gel | Longitudinal Analysis of the stomatognathic system in adult patients undergoing Treatment for Muscular Temporomandibular Disorder associated with Cannabidiol | RBR-6xfb4xs |
| Cannabidiol After Multi-Trauma for Pain and Opioid Therapy | Effects of an Acute 1-month Cannabidiol Treatment on Pain and Inflammation After a Long Bone Fracture: a Triple-blind Randomized, Placebo Controlled Clinical Trial | NCT06448923 |
| CBD for Knee Osteoarthritis | Sub-Lingual Administration of Cannabidiol for Knee Osteoarthritis | NCT06414473 |
| Topical CBD's Effects on Soreness and Performance | The Effects of Cannabidiol (CBD) Cream on Delayed Onset Muscle Soreness (DOMS and Performance After Exercise | NCT06320327 |
| Treating anxiety in young people (12-25 years) using Cannabidiol (CBD) when conventional anxiety treatments have proven ineffective. | Efficacy of Cannabidiol for Youth with Inadequate Clinical Response to Anxiety Treatments - A Randomised Controlled Trial | ACTRN12624000236594 |
| Evaluation of the effects of a single dose of Cannabidiol on attention and memory in people with Obsessive Compulsive Disorder | Analysis of the effects of Acute Cannabidiol Administration on Attention and Memory Bias in Patients with Obsessive Compulsive Disorder | RBR-5dbqvhd |
| Cannabidiol and Older Adult Cannabis Users | Rocky Mountain Cannabis Research Center - Cannabidiol and Older Adult Cannabis Users: A Randomized, Placebo-Controlled Study | NCT06290063 |
| Use of Cannabidiol in the treatment of psychiatric symptoms of Vascular Dementia | Effects of Cannabidiol on behavioral and psychological symptoms of Vascular Dementia | RBR-686kmpz |
| Use of CBD in the Treatment of Anxiety | A Pilot Double-Blind Placebo-Controlled, Randomized, Safety, Efficacy, and Acceptability Trial of a Hemp-Derived Cannabidiol Extract for the Treatment of Anxiety | NCT06672666 |
| MIVetsCan: Cannabidiol (CBD)-Care Trial | Pragmatic Trial of Cannabidiol to Improve Chronic Pain Symptoms Among Veterans | NCT06213233 |
| The CanOPY Study: The efficacy of cannabidiol in addition to standard treatment in first episode psychosis in young people | The efficacy of cannabidiol adjunct to standard treatment in reducing positive psychotic symptoms in young people with first episode psychosis | ACTRN12624001303538 |
| A clinical trial of the preliminary effectiveness of topical cannabidiol (CBD) on function, joint pain and swelling, and inflammation in adults with rheumatoid arthritis | An open label clinical trial investigating the preliminary effectiveness of a topical cannabidiol (CBD) roll-on salve on functional status, joint pain and swelling, and inflammation in adults with rheumatoid arthritis (RA). | ACTRN12624001378516 |
| Modulaton of stress analgesia with tetrahydrocannabinol or cannabidiol | Modulaton of stress analgesia with tetrahydrocannabinol or cannabidiol - LOGIN-TS4 | DRKS00005442 |
| Processing of Salient Emotional Stimuli as a Function of Tetrahydrocannabinol (THC) and Cannabidiol (CBD) | Processing of Salient Emotional Stimuli as a Function of Tetrahydrocannabinol (THC) and Cannabidiol (CBD) | NCT02291536 |
| Effects of THC and CBD on Human Episodic Memory Function | Effects of D-9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD) on Human Episodic Memory Function | NCT02291562 |
| Treatment of Chronic Pain With Cannabidiol (CBD) and Delta-9-tetrahydrocannabinol (THC) | Treatment of Chronic Pain With Cannabidiol (CBD) and Delta-9-tetrahydrocannabinol (THC): Effectiveness, Side Effects and Neurobiological Changes | NCT03215940 |
| A Randomised, Double Blind, Placebo-Controlled Trial of Medicinal Cannabis in Adults with Tourette's Syndrome | A Randomised, Double Blind, Placebo-Controlled, Crossover Trial of Tetrahydrocannabinol and Cannabidiol for the treatment of Tourette’s Syndrome | ACTRN12618000545268 |
| EP1 cannabidiol enriched cannabis oil in refractory epilepsy | A Double-blind, Placebo-controlled Study Investigating the Safety, Tolerability, Efficacy and Pharmacokinetics of EP1, an Enriched Cannabidiol Oil, in Children and Adolescents with Medication Resistant, Refractory Epilepsy | ACTRN12618001706268 |
| Cannabidiol 100 mg/ml Oral Solution as Add-on therapy for Seizures in Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS) | An observational, Prospective, Multicenter Study to evaluate safety of cannabidiol 100 mg/ml oral solution as add-on therapy in patients with for Seizures Associated with Lennox-Gastaut Syndrome (LGS) or Dravet Syndrome (DS) - NIL | CTRI/2025/06/088828 |
| Can cannabidiol help in the treatment of depression in patients with bipolar disorder? | Cannabidiol Adjunctive Therapy for Acute Bipolar Depression: A Randomized Double-Blind, Placebo Controlled Trial - NIL | CTRI/2025/05/087476 |
| Effect of an Experimental Cannabidiol Gel on Tooth Sensitivity | Effect of an Experimental Cannabidiol Gel on Tooth Sensitivity Induced by Tooth Bleaching | NCT07027566 |
| Oral Bioequivalence Study of Cannabidiol (CBD) 600 mg Tablets in healthy volunteers under fasting study. | An Open Label, Single-Center, Balanced, Randomized, Multi-Dose, Two-Treatment, Two-Sequence, Two-Period, Crossover Oral Bioequivalence Study Comparing Test Product (T) Encapsulated Nano-Cannabidiol-600mg, uncoated tablets manufactured by Dhee Lifesciences with Reference Product (R) EPIDIOLEX (cannabidiol) oral solution 100mg/mL Distributed by Jazz Pharmaceuticals, Manufactured By: GW Pharmaceuticals plc. in Healthy, Adult, Human Subjects Under Fasting Conditions. - Nil | CTRI/2025/04/085828 |
| Adjunctive Cannabidiol for Recovery From Opioid Study | Adjunctive Cannabidiol for Recovery From Opioid Study (ACROS) | NCT06940674 |
| Cannabidiol in Sickle Cell Disease | Treatment of Sickle Cell Pain and Inflammation With Cannabidiol (SPICe) | NCT06930703 |
| Safety and Pharmacokinetics of Cannabidiol in Healthy Volunteers | A Phase 1, Open-Label, Multiple Dose Study to Assess the Pharmacokinetics, Safety, Tolerability, and Food Effect of MRX1 in Healthy Adults | NCT06854783 |
| A Trial to Investigate the Effects of Cannabidiol Plus Naltrexone on Alcohol Craving in Patients With Alcohol Dependence | ICONICplus - Randomized, Double-blind, Placebo-controlled Trial to Investigate the Effects of Cannabidiol Plus Naltrexone on Cue-Induced Alcohol Craving in Alcohol Dependence | NCT06845124 |
| Efficacy and safety of cannabidiol to patients with advanced prostate cancer | Efficacy and safety of cannabidiol for pain relief of patients with end-stage metastatic castration resistant prostate cancer - a randomised double-blinded placebo-controlled phase II trial (ProCan) | CTIS2024-513951-33-00 |
| The Effects of Cannabidiol on the Driving Performance of Healthy Adults by Dose and Sex | The Effects of Cannabidiol on the Driving Performance of Healthy Adults by Dose and Sex | NCT06686914 |
| Cannabidiol in the Treatment of Opioid Use Disorder | Cannabidiol in the Treatment of Opioid Use Disorder | NCT06206291 |
| Cannabidiol for Reducing Cigarette Use | Evaluating the Efficacy of Cannabidiol for Reducing Cigarette Use | NCT06218056 |
| Cannabidiol Effects on Fear Extinction in Social Phobia | Cannabidiol Effects on Fear Extinction in Social Phobia | NCT06123702 |
| CBD for Individuals at Risk for Alzheimer's Disease | Cannabidiol for Individuals at Risk for Alzheimer's Disease: A Randomized Placebo Controlled Trial | NCT05822362 |
| Effects of Inclusion of Cannabidiol in the Usual Treatment of Obsessive Compulsive Disorder | Clinical effects of the addition of cannabidiol to the usual treatment of patients with diagnosis of Obsessive Compulsive Disorder | RBR-467ksmb |
| Cannabidiol in Children and Young Adults With Rare Disease-associated Severe Epilepsy | Open-label Pilot Study to Assess the Efficacy and Safety of Cannabidiol Oral Solution as an Adjunctive Treatment for Children and Young Adults With Rare Disease-associated Severe Epilepsy | NCT05803434 |
| A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients | A Randomized, Double-blind, Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients | NCT05753007 |
| Randomised double-blind, comparative study to Evaluate the Efficacy, Safety of Cannabidiol oral solution versus matching Placebo for treatment of mild to moderate anxiety disorders | A prospective, randomised, double-blind, multicenter comparative study to Evaluate the Efficacy, Safety and Pharmacokinetics of Cannabidiol oral solution versus matching Placebo for treatment of mild to moderate anxiety disorders. - CP-CBD001-22 | CTRI/2023/01/049110 |
| Effectiveness of 0.5% Cannabidiol in Alcohol Solution versus Alcohol Solution on Skin Barrier Function: Crossover Randomized Controlled Trial | Effectiveness of 0.5% Cannabidiol in Alcohol Solution versus Alcohol Solution on Skin Barrier Function: Crossover Randomized Controlled Trial | TCTR20230110001 |
| A study that evaluates the effectiveness of oral combined THC/CBD for people with advanced cancer experiencing a range of symptoms. | Oral Medicinal cannabinoids to Relieve Symptom Burden in the Palliative care of Patients with Advanced cancer: a double-blind, placebo controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) | ACTRN12619000037101 |
| CBD, Immune Function, and Neural Health | Are Natural Killer Cells Novel Mediators of the Effects of Cannabidiol on Physical Fitness, Mental Health and Well-Being, Sleep Quantity, Sleep Quantity and Immune Function? | NCT04881539 |
| Excretion and side effects for tetrahydrocannabinol and cannabidiol (Sativex) among patients with chronic kidney disease and patients on dialysis. | Pharmacokinetics and side effects for tetrahydrocannabinol and cannabidiol (Sativex) among patients with chronic kidney disease and patients on dialysis. - PK cannabinoids | EUCTR2019-002786-35-DK |
| Efficacy And Withdrawal Symptoms in Transition Between Cannabidivarin (CBDV) and Cannabidiol (CBD) in Children with Rett Syndrome and Refractory Epilepsy | Efficacy And Withdrawal Symptoms in Transition Between CBDV to CBD in Children with Rett Syndrome and Refractory Epilepsy | ACTRN12624000948594 |
| Do blood, saliva and urine levels of THC and cannabidiol (chemicals found in cannabis) relate to their effects on personality and perception | Tissue Levels of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) and Effects on Perception and Personality in healthy volunteers | ACTRN12621000142831 |
| Do Adolescents and Adults Differ in Their Acute Response to Cannabis? | Do Adolescents and Adults Differ in Their Acute Subjective, Behavioural and Neural Responses to Cannabis, With and Without Cannabidiol? | NCT04851392 |
| The effect of using Cannabidiol on the severity of spasticity in MS patients with gait disorders | Effects of oral cannabidiol (CBD) usage on variable severity of spasticity in multiple sclerosis patients with gait problem caused by their spasticity. A Double-Blind Randomised Controlled Trial | IRCT20220815055709N1 |
| Evaluation of the Efficacy of CANNABIDIOL on the Pruritus in Children With Hereditary Epidermolysis Bullosa | Evaluation of the Efficacy of CANNABIDIOL on the Pruritus in Children With Hereditary Epidermolysis Bullosa | NCT05651607 |
| Topical CBD Scar Outcomes Study | The Effects of Topical Cannabidiol on Paramedian Forehead Flap Scar Healing: A Split Scar Study | NCT05650697 |
| Cannabidiol to Reduce Anxiety Reactivity | Endocannabinoid System Engagement to Reduce Anxiety Reactivity with Cannabidiol in Social Anxiety Disorder (R61 Project) | NCT05823753 |
| The Use of Cannabis (Marijuana) and Cannabidiol (CBD) Among Cancer Patients: A Pilot Study | The Use of Cannabis (Marijuana) and Cannabidiol (CBD) Among Cancer Patients: A Pilot Study | NCT05836857 |
| A Randomised, Double-Blind, Placebo-Controlled, Parallel-Arm Study to Evaluate the Efficacy, Safety and Tolerability of 150 mg Sublingual Cannabidiol in Adults with Mild-to-Moderate Pain. | A Randomised, Double-Blind, Placebo-Controlled, Parallel-Arm Study to Evaluate the Efficacy, Safety and Tolerability of 150 mg Sublingual Cannabidiol in Adults with Mild-to-Moderate Pain. | ACTRN12623000404628 |
| Cannabidiol Oil Extract for Prevention of Postoperative Nausea and Vomiting | Sublingual Cannabidiol Oil Extract for Prevention of Postoperative Nausea and Vomiting in Elective Gynaecological Patients at the University Hospital of the West Indies (UHWI) | NCT06137027 |
| Cannabidiol Effects on Blood Alcohol Level and Intoxication | Exploring the Effects of Acute Cannabidiol Administration on Blood Alcohol Level and Intoxication in Adult Human Subjects | NCT06105138 |
| Evaluation of the use of Cannabidiol in Third Molar Extraction | Evaluation of the use of Cannabidiol in Third Molar Extraction Surgeries | RBR-8rv93wn |
| Longitudinal Outpatient Treatment for Cannabis Use Disorder | Hemp-derived Cannabidiol for the Treatment of Cannabis Use Disorder: A Double-blind Placebo-controlled Randomized Trial | NCT06107062 |
| Study of Cannabidiol (CBD) in Healthy Volunteers | An Open-Label Parallel Phase I Study Evaluating Multiple Ascending Dose Pharmacokinetics and Acute Immunomodulatory Potential of a Novel Oral Cannabidiol (CBD) Formulation | NCT06286839 |
| Topical Cannabidiol for Treating Carpal Tunnel Syndrome | A Randomized Controlled Trial of Topical Cannabidiol for the Treatment of Carpal Tunnel Syndrome | NCT06108349 |
| The Effect of Cannabidiol in Learning and Memory of Adults | The Effect of Cannabidiol in Learning and Memory of Adults | NCT06074172 |
| A study measuring cannabidiol uptake to the bloodstream from novel cannabidiol-containing food products | A randomised, controlled, single-centre, open-label study to assess the pharmacokinetics of cannabidiol in tincture, shot and chew products in healthy adult subjects | ISRCTN69161830 |
| Cannabidiol, Morphine, Pain | Human Laboratory Model to Screen Drugs With Opioid Analgesic-sparing Effects: Cannabidiol/Morphine Combinations | NCT04030442 |
| Comparative trial on the effectiveness of topical cannabidiol based on different adhesion times in healthy individuals. | Cannabidiol Topical Application - Time's Influence on Modulation of Effectiveness Study - CBD-TIME Study | JPRN-jRCT1031230303 |
| Efficacy and Safety of Low-dose Cannabidiol for anxiety | Efficacy and Safety of Low-dose Cannabidiol for anxiety in adults: A randomised, double-blind placebo-controlled study | ACTRN12623000803695 |
| Efficacy and Safety of Low-dose Cannabidiol for treatment of sleep disturbances | Efficacy and Safety of Low-dose Cannabidiol for treatment of sleep disturbances in adults: A randomised, double-blind placebo-controlled study | ACTRN12623000802606 |
| Cannabidiol as a treatment in patients with movement disorder | Cannabidiol as a therapy for spinocerebellar ataxia | RBR-36x4c4d |
| CBD Knee Scope Study | Effectiveness of Cannabidiol vs. Narcotics for Post Operative Pain Control in Elective Knee Arthroscopic Surgery | NCT05934500 |
| Does cannabidiol enhance exercise enjoyment? A randomised controlled trial. | The effect of cannabidiol on affective responses to self-paced aerobic exercise in healthy adults: A randomised, double-blind, placebo-controlled, crossover trial. | ACTRN12623000593639 |
| Effects of CBD Oil on Memory Reconsolidation and Trauma-Related Symptoms | Effects of Cannabidiol on Memory Reconsolidation and Trauma-Related Symptoms: A Randomized Clinical Trial | NCT05892276 |
| Cannabidiol for Bipolar Depression (CBD-BD) | Cannabidiol Adjunctive Therapy for Acute Bipolar Depression: A Randomized Double-Blind, Placebo Controlled Trial | NCT05867849 |
| The effects of cannabidiol (CBD) on psychosocial stress, situational anxiety and nausea experienced in a virtual reality environment | A randomised, double-blind, placebo-controlled, parallel-group trial exploring the effect of purified oral cannabidiol (CBD) on psychosocial stress, situational anxiety, acute motion sickness and cybersickness experienced in a virtual reality environment in healthy individuals. | ACTRN12623000872639 |
| Evaluation of the effect of cannabidiol in the treatment of schizophrenic patients | The effect of cannabidiol on positive symptoms in schizophrenic patients | IRCT20210310050660N2 |
| CASCADE: CAnnabidiol Study in Children With Autism Spectrum DisordEr | CAnnabidiol Study in Children With Autism Spectrum DisordEr (CASCADE): A Double-Blind, Placebo-Controlled Study to Investigate Efficacy and Safety of Cannabidiol in Children and Adolescents With Autism | NCT04520685 |
| Effects of Cannabidiol (CBD) on the Brain | Effects of Cannabidiol (CBD) on the Brain | NCT04831294 |
| Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults | A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults. | NCT02224560 |
| GWPCARE5 - An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet or Lennox-Gastaut Syndromes | An Open Label Extension Study to Investigate the Safety of Cannabidiol (GWP42003-P; CBD) in Children and Young Adults With Inadequately Controlled Dravet or Lennox-Gastaut Syndromes. | NCT02224573 |
| The effect of cannabidiol (40mg) on fear conditioning | The effect of cannabidiol in facilitating fear extinction and in attenuating fear retention and reinstatement | NL-OMON28165 |
| Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder | A Multicenter, Open-label, Flexible Dose Study to Assess the Long-term Safety of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Treatment for Pediatric Subjects With a Treatment-resistant Seizure Disorder Who Complete INS011-14-029 or Part A of INS011-15-054 | NCT02318602 |
| Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Lennox-Gastaut Syndrome | A Multicenter, Randomized, Double-blind, Placebo-controlled, Interventional Study to Assess the Safety and Efficacy of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Subjects With Inadequately Controlled Lennox-Gastaut Syndrome | NCT02318537 |
| Cannabidiol Oral Solution in Pediatric Participants With Treatment-resistant Seizure Disorders | A Phase 1/2 Study to Assess the Pharmacokinetics and Safety of Multiple Doses of Pharmaceutical Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Seizure Disorders | NCT02324673 |
| Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Dravet Syndrome | A Multicenter, Randomized, Double-blind, Placebo- Controlled, Interventional Study to Assess the Safety and Efficacy of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Subjects With Inadequately Controlled Dravet Syndrome | NCT02318563 |
| Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome | Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome | NCT02332655 |
| GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome | A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome. | NCT02224703 |
| A study to investigate the possible interaction between clobazam and cannabidiol. | A phase 2, double-blind, randomized, placebo-controlled study to investigate possible drug-drug interactions between clobazam and cannabidiol (GWP42003-P) | EUCTR2014-002942-33-GB |
| Cannabidiol enhancement of exposure therapy in patients with phobias. | Cannabidiol enhancement of exposure therapy in treatment refractory patients with phobias. | NL-OMON28305 |
| Treatment of Drug Resistant Epilepsy | Physician Expanded Access to Investigational New Drug Cannabidiol for the Treatment of Drug Resistant Epilepsy | NCT02461706 |
| A study that evaluates the effectiveness of oral medicinal cannabis for people with advanced cancer experiencing a range of symptoms. | Oral Medicinal Cannabinoids to Relieve Symptom Burden in the Palliative Care of Patients with Advanced Cancer: a double-blind, placebo controlled, randomised clinical trials of efficacy and safety of cannabidiol (CBD) | ACTRN12618001220257 |
| Extended Use of Cannabidiol for the Prevention of Graft-versus-host-disease | Extended Use of Cannabidiol for the Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Cell Transplantation | NCT02478424 |
| Cannabidiol Treatment in Patients With Early Psychosis | Cannabidiol Treatment in Patients With Early Psychosis | NCT02504151 |
| Sublingual Cannabidiol for Anxiety | Sublingual Cannabidiol for Anxiety | NCT02548559 |
| Clinical study Of caNNabidiol in childrEn and adolesCenTs with Fragile X(CONNECT-FX) | A Randomized, Double-Blind, Placebo-Controlled Multiple-Center, Efficacy andSafety Study of ZYN002 Administered as a Transdermal Gel to Children andAdolescents with Fragile X Syndrome – CONNECT-FX | ACTRN12618001063202 |
| The effect of cannabidiol (40mg) on fear conditioning | The effect of cannabidiol (40mg) on fear conditioning - The effect of cannabidiol (40mg) on fear conditioning | NL-OMON42213 |
| Cannabidiol for the Treatment of Severe (Grades III/IV) Acute Graft-versus-host Disease | Cannabidiol for the Treatment of Severe (Grades III/IV) Acute Graft-versus-host Disease | NCT02392780 |
| A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults | A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults. | NCT02224690 |
| A study of the safety, pharmacokinetics and efficacy of cannabidiol (GWP42003-P) in children and young adults with Dravet syndrome | A double-blind, placebo-controlled two-part study to investigate the dose-ranging safety and pharmacokinetics, followed by the efficacy and safety of cannabidiol (GWP42003-P) in children and young adults with Dravet syndrome. | EUCTR2014-000995-24-GB |
| Cannabidiol (CBD) to 27 Patients (Aged 2 Years - 19 Years) With Drug Resistant Epilepsy | A 2-part Study to Investigate the Dose-ranging Pharmacokinetics and Tolerability, Followed by the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With | NCT02286986 |
| Cannabidiol for Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Stem Cell Transplantation | Safety and Efficacy of Oral Cannabidiol for GVHD Prophylaxis in Allogeneic Stem Cell Transplantation | NCT01385124 |
| Acute and Short-term Effects of Cannabidiol Admin on Cue-induced Craving in Drug-abstinent Heroin Dependent Humans | Cannabidiol as Treatment Intervention for Opioid Relapse | NCT01605539 |
| Safety and Efficacy of Cannabidiol for Grade I/II Acute Graft Versus Host Disease (GVHD) After Allogeneic Stem Cell Transplantation | Safety and Efficacy of Cannabidiol for Grade I/II Acute Graft Versus Host Disease (GVHD) After Allogeneic Stem Cell Transplantation | NCT01596075 |
| A randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of cannabidiol oral solution (GWP42003-P; CBD-OS) in patients with Rett syndrome. | A randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of cannabidiol oral solution (GWP42003-P; CBD-OS) in patients with Rett syndrome. | EUCTR2018-003370-27-GB |
| Cannabidiol Effects on Craving and Relapse Prevention in Opioid Use Disorder | Cannabidiol Effects on Craving and Relapse Prevention in Opioid Use Disorder | NCT03787628 |
| The effect of Cannabidiol (CBD) on paranoid cognitions in humans | The effect of Cannabidiol (CBD) on paranoid cognitions in humans: a randomised controlled trial | ISRCTN11082858 |
| Clinical study Of caNNabidiol in children and adolesCenTs with Fragile X Open-Label Extension (CONNECT-FX OLE) | An Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of ZYN002 Administered as a Transdermal Gel to Children and Adolescents with Fragile X Syndrome – CONNECT-FX Open Label Extension (OLE) | ACTRN12618001868279 |
| Cannabidiol: a novel intervention for cannabis use problems? | A phase IIa/b, randomised, double-blind, placebo-controlled, single-site, parallel group clinical trial to examine cannabidiol (CBD) as a pharmacological treatment for cannabis dependence in a young cannabis dependent population. - Cannabidiol: a novel intervention for cannabis use problems? | EUCTR2013-000361-36-GB |
| Does cannabidiol reduce severe behavioural problems in youth with intellectual disability? Feasibility and pilot randomised placebo-controlled trial. | Pilot study of cannabidiol (CBD) in children with Intellectual Disability (ID) and Severe Behavioural Problems (SBP) | ACTRN12618001852246 |
| A four-week clinical trial investigating efficacy and safety of cannabidiol as a treatment for acutely ill schizophrenic patients | A four-week, multicentre, double-blinded, randomised, active- and placebo-controlled, parallel-group trial investigating efficacy and safety of cannabidiol in acute, early-stage schizophrenic patients | EUCTR2012-004335-23-DE |
| Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study | Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study With Approved Antipsychotics in Vivo | NCT02051387 |
| Cannabidiol for Drug Resistant Pediatric Epilepsy (Expanded Access Use) | Cannabidiol (CBD) Cannabis Extract Oral Solution for Drug Resistant Pediatric Epilepsy (Expanded Access Use) | NCT03676049 |
| Cannabidiol for the treatment of patients at a high-risk of psychosis | CANnabidiol as a Treatment fOr clinical high-risk state Psychosis - a Randomised Clinical Trial (CANTOP-RCT) | ISRCTN10334895 |
| Investigation of the safety, tolerability and pharmacokinetics of Cannabidiol in Healthy Volunteers | A Phase 1, Randomised, Placebo-controlled, Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Cannabidiol in Healthy Volunteers | ACTRN12618001424291 |
| Cannabidiol as an add-on therapy in treatment-refractory psychotic disorders | Cannabidiol as an add-on therapy in treatment-refractory psychotic disorders - CBD_ADD_IN | EUCTR2013-000240-26-GB |
| Cannabidiol: a Novel Intervention for Cannabis Use Problems? | A Phase IIa/b, Randomised, Double-blind, Placebo-controlled, Single-site, Parallel Group Clinical Trial to Examine Cannabidiol (CBD) as a Pharmacological Treatment for Cannabis Dependence. | NCT02044809 |
| Cannabidiol (CBD) for the Management of Cannabis Withdrawal: A Phase II Proof of Concept Study | Cannabidiol (CBD) for the Management of Cannabis Withdrawal: A Phase II Proof of Concept Study | ACTRN12614000248662 |
| A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol As a Treatment for Acutely Ill Schizophrenic Patients | A Four-week, Multicentre, Double-blinded, Randomised, Active- and Placebo- Controlled, Parallel-group Trial Investigating Efficacy and Safety of Cannabidiol in Acute, Early-stage Schizophrenic Patients | NCT02088060 |
| Cannabidiol in Patients With Heart Failure Failure in AHA/ACC Stages A-C | Phase I, Single Center, Open-label Study of Cannabidiol in Patients With Heart Failure in AHA/ACC Stages A-C | NCT03634189 |
| An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6) | A Double-blind, Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P, CBD) as Add-on Therapy in Patients With Tuberous Sclerosis Complex Who Experience Inadequately-controlled Seizures | NCT02544750 |
| Does adding cannabidiol (a component of cannabis) enhance the treatment of phobias where patients are confronted with their fears (exposure treatment). | Cannabidiol enhancement of exposure therapy in treatment refractory patients with phobias. - Cannabidiol in the treatment of phobic anxiety disorders | EUCTR2014-004094-17-NL |
| Cannabidiol Oral Solution for Treatment of Refractory Infantile Spasms | A Phase 2 Study to Assess the Efficacy and Safety of Cannabidiol Oral Solution for the Treatment of Refractory Infantile Spasms | NCT02551731 |
| Cannabidiol for Pediatric Epilepsy (Compassionate Use) | Cannabidiol for the Treatment of Pediatric Epilepsy (Expanded Access/Compassionate Use Protocol) | NCT02556008 |
| Cannabidiol as an Adjunctive Treatment for Bipolar Depression | A Double-blind, Randomized, Placebo-controlled Clinical Trial of Adjunctive Cannabidiol for Bipolar Depression | NCT03310593 |
| Does cannabidiol treatment lead to recovery of brain structure and function in cannabis users? | Does cannabidiol treatment lead to recovery of brain structure and function in cannabis users? A pilot investigation | ISRCTN89498802 |
| Cannabidiol as a Treatment for AUD Comorbid With PTSD | Cannabidiol as a Treatment for Alcohol Use Disorder Comorbid With Posttraumatic Stress Disorder | NCT03248167 |
| Effects of Cannabidiol in Alcohol Use Disorder | Effects of Cannabidiol in Alcohol Use Disorder | NCT03252756 |
| The buccal administration of a NanoCelle™ Cannabidiol formulation to healthy volunteers: a pharmacokinetic, safety and tolerability exploratory pilot study. | The buccal administration of a NanoCelle™ Cannabidiol formulation to healthy volunteers: a pharmacokinetic, safety and tolerability exploratory pilot study. | ACTRN12617001491358 |
| A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease | A Randomized, Double Blind, Placebo-controlled Parallel Study of Tolerability and Efficacy of Cannabidiol (CBD) on Motor Symptoms in Parkinson's Disease | NCT03582137 |
| Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures | A Phase 2, Open-label, Dose-finding Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Patients With Treatment-Resistant Childhood Absence Seizures | NCT03336242 |
| Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures | A Multicenter, Open-Label, Flexible Dose Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Patients With Treatment-Resistant Childhood Absence Seizures | NCT03355300 |
| Cannabidiol and Prolonged Exposure | Cannabidiol as an Adjunctive to Prolonged Exposure for the Treatment of PTSD | NCT03518801 |
| The effect of cannabidiol (300 mg) on fear conditioning. | The effect of cannabidiol in facilitating fear extinction and in attenuating fear retention and reinstatement in humans. | NL-OMON28474 |
| Clinical study of Cannabidiol in children and adolescents with Developmental and Epileptic Encephalopathy | Open Label Study to Assess the Safety and Efficacy of ZYN002 Administered as a Transdermal Gel to Children and Adolescents (3 to <18 years) with Developmental and Epileptic Encephalopathy (BELIEVE 1) | ACTRN12618000516280 |
| Cannabis based medication for the treatment of pain generated in the nervous system. | Tetra-hydro-cannabinol, cannabidiol and their combination for the treatment of peripheral neuropathic pain. A randomised placebo-controlled trial. - THC, CBD and their combination for treatment of peripheral neuropathic pain | EUCTR2017-005198-38-DK |
| The CANBACK trial, to determine the efficacy of oral cannabidiol, when compared to placebo, as an adjunct for the treatment of acute non-traumatic low back pain. | A randomized, double-blinded, placebo-controlled, clinical trial assessing the efficacy of CANnabidiol for reducing BACK pain in the emergency department (CANBACK) | ACTRN12618000487213 |
| The effect of cannabidiol in facilitating fear extinction and in attenuating fear retention and reinstatement in humans | The effect of cannabidiol in facilitating fear extinction and in attenuating fear retention and reinstatement in humans - The effect of cannabidiol (300 mg) on fear conditioning | NL-OMON46397 |
| Cannabidiol - an in Vivo Innovative Drug Delivery Study | Cannabidiol as a Medication for Neuropsychiatric and Other Medical Conditions - an in Vivo Innovative Drug Delivery Study | NCT03471559 |
| Cannabidiol Usage as an Adjunct Therapy for Crohn's Disease | Oral Cannabidiol Capsule Usage as an Adjunct Therapy for Crohn's Disease: a Randomized, Placebo-controlled Study | NCT03467620 |
| A Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Patients With Prader-Willi Syndrome | A Multicenter, Open-Label Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Patients With Prader-Willi Syndrome | NCT03458416 |
| A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With Dravet Syndrome or Lennox Gastaut Syndrome Currently Taking Cannabidiol | An Open-Label Trial to Assess the Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Combination With Cannabidiol, as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome or Lennox-Gastaut Syndrome | NCT03467113 |
| A Study to Assess the Efficacy, Safety, and Tolerability of Cannabidiol Oral Solution With Vigabatrin as Initial Therapy in Participants With Infantile Spasms | A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of Cannabidiol Oral Solution as Adjunctive Therapy With Vigabatrin as Initial Therapy in Patients With Infantile Spasms | NCT03421496 |
| The cannabidiol youth anxiety pilot study (CAPS): a 12-week open- label pilot study of cannabidiol for anxiety disorders | The cannabidiol youth anxiety pilot study (CAPS): a 12-week open- label pilot study of the safety, tolerability and efficacy of cannabidiol for anxiety disorders | ACTRN12617000825358 |
| Study to Test the Safety and Efficacy of Cannabidiol as a Treatment Intervention for Opioid Relapse | Cannabidiol as Treatment Intervention for Opioid Relapse | NCT01311778 |
| The Pharmacokinetics and Pharmacodynamics of Oral and Vaporized Cannabidiol | The Pharmacokinetics and Pharmacodynamics of Oral and Vaporized Cannabidiol | NCT03164512 |
| Cannabidiol for the Treatment of Anxiety Disorders: An 8-Week Pilot Study | Cannabidiol for the Treatment of Anxiety Disorders: An 8-Week Pilot Study | NCT03549819 |
| Cannabidiol and Cocaine Craving/Dependence | Cannabidiol as a New Treatment for Cocaine Addiction | NCT02559167 |
| A Randomized Controlled Trial to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol | A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol (GWP42003-P) | NCT02565108 |
| A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P; CBD) as adjunctive treatment for seizures associated with Lennox- Gastaut syndrome in children and adults | A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P; CBD) as adjunctive treatment for seizures associated with Lennox- Gastaut syndrome in children and adults - GWEP1423 | NL-OMON42107 |
| An Open-label Extension Trial to Investigate Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy | A Phase 2, Double-blind, Randomized, Placebo-controlled Pharmacokinetic Trial in 2 Parallel Groups to Investigate Possible Drug-drug Interactions Between Stiripentol or Valproate and GWP42003-P in Patients With Epilepsy | NCT02607904 |
| A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies | Randomized Double-Blind, Placebo-Controlled Parallel Multi-Center Study to Assess the Efficacy of Cannabidiol (BRCX014) Combined With Standard-Of-Care Treatment in Subjects With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies | NCT03607643 |
| Safety and Tolerability of Cannabidiol in Subjects With Drug Resistant Epilepsy | Safety and Tolerability of Cannabidiol in Subjects With Drug Resistant Epilepsy | NCT02660255 |
| An 8-week randomized, double-blind, placebo-controlled clinical trial of Cannabidiol as add-on therapy in bipolar depression | Cannabidiol in Bipolar Depression – CannaBiD-Study: An 8-week randomized, double-blind, placebo-controlled clinical trial of Cannabidiol as add-on therapy in bipolar depression - CannaBiD-Study | EUCTR2015-000465-31-DE |
| Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype | Mechanisms of Cannabidiol (CBD) in Persons With Multiple Sclerosis (MS): the Role of Sleep and Pain Phenotype | NCT05269628 |
| A Study of Tolerability and Efficacy of Cannabidiol on Tremor in Parkinson's Disease | A Randomized, Double Blind, Placebo-controlled Crossover Study of Tolerability and Efficacy of Cannabidiol (CBD) on Tremor in Parkinson's Disease | NCT02818777 |
| A Double-Blind Trial to Evaluate Efficacy and Safety of Cannabidiol as an add-on Therapy for Treatment in Refractory Epilepsy | A Double-blind, Randomized Placebo-controlled Trial to Evaluate Efficacy and Safety of Cannabidiol as an add-on Therapy for Treatment in Refractory Epileptic Crisis in Children and Adolescents | NCT02783092 |
| The Effects of Cannabidiol (CBD) on Electrical and Autonomic Cardiac Function in Children With Severe Epilepsy | The Effects of Cannabidiol (CBD) on Electrical and Autonomic Cardiac Function in Children | NCT02815540 |
| Enhancing Recovery in Early Schizophrenia | Enhancing Recovery in Early Schizophrenia - a Multi-center, Two-arm, Double-blind, Randomized Phase II Trial Investigating Cannabidiol Vs. Placebo As an Add-on to an Individualized Antipsychotic Treatment | NCT02926859 |
| A study of cannabidiol (GWP42003-P, CBD) in patients with tuberous sclerosis complex who experience seizures. | A double-blind, randomized, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P, CBD) as add-on therapy in patients with tuberous sclerosis complex who experience inadequately-controlled seizures | EUCTR2015-002154-12-ES |
| Cannabidiol Oral Solution for the Treatment of Subjects With Prader-Willi Syndrome | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of Cannabidiol Oral Solution for the Treatment of Subjects With Prader-Willi Syndrome | NCT02844933 |
| Cannabidiol and Emotional Stimuli | Effects of Cannabidiol on Responses to Emotional Stimuli | NCT02902081 |
| Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms (GWPCARE7) | A Randomized, Double-blind, Placebo-controlled Trial to Investigate the Efficacy and Safety of Cannabidiol (CBD; GWP42003-P) in Infants With Infantile Spasms Following an Initial Open-label Pilot Study | NCT02953548 |
| The effect of CanChew®, cannabidiol (CBD) containing chewing gum on Irritable Bowel Syndrome | The effect of CanChew®, cannabidiol (CBD) containing chewing gum on Irritable Bowel Syndrome - The CANdidate study | NL-OMON43003 |
| Study of Cannabidiol for Drug-Resistant Epilepsies | A Phase 1/2, Safety, Tolerability, and Dose-Finding Study of Cannabidiol for Drug-Resistant Epilepsies | NCT03014440 |
| Expanded Use of Cannabidiol Oral Solution | A Multicenter, Open-label, Flexible Dose Study to Assess the Long-term Safety of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Treatment for Pediatric Subjects With a Treatment-resistant Seizure Disorder Who Complete INS011-14-029 or Part A of INS011-15-054 | NCT03196934 |
| Cannabidiol Pharmacotherapy for Adults With Cannabis Use Disorder | Cannabidiol Pharmacotherapy for Adults With Cannabis Use Disorder | NCT03102918 |
| Clinical Study of Synthetic Cannabidiol in Children and Adolescents with Autism Spectrum Disorder | An Open-Label, Single-Center, Tolerability and Efficacy Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents with Autism Spectrum Disorder | ACTRN12619000216112 |
| Effects of Cannabidiol on Psychiatric Symptoms, Cognition, and Cannabis Consumption in Cannabis Users With Recent-Onset Psychosis | Effects of Cannabidiol on Psychiatric Symptoms, Cognition, and Cannabis Consumption in Cannabis Users With Recent-Onset Psychosis | NCT03883360 |
| The Effects of Cannabidiol and ?-9-THC in Humans | Cannabidiol Modulation of ?-9-THC's Psychotomimetic Effects in Healthy Humans | NCT01180374 |
| Multi-centre trial of cannabidiol (CBD) for the treatment of Parkinson's disease psychosis | CANnabidiol for Parkinson’s Disease Psychosis (CAN-PDP) | ISRCTN87895237 |
| A study of the safety and tolerability of single doses of wafers containing cannabidiol (CBD) that dissolve under the tongue compared to CBD oil that is swallowed in healthy volunteers. | A phase I, open label, two-way crossover study to determine the pharmacokinetic effects, safety, and tolerability of single doses of sublingual cannabidiol wafers vs. cannabidiol oil in healthy volunteers | ACTRN12620000891921 |
| The Effect of Cannabidiol on Lean Body Mass in Patients Receiving Chemotherapy | The Effect of Medical Cannabidiol on Lean Body Mass in Patients Receiving Oxaliplatin or Paclitaxel Based Chemotherapy | NCT04585841 |
| Cannabidiol and Management of Endometriosis Pain | A Randomized Controlled Pilot Study of the Use of Cannabidiol in the Management of Endometriosis Pain | NCT04527003 |
| Explorative, randomized, double-blind, placebo-controlled, 3-way cross-over study to assess the effects of oral cannabidiol 160 and 1500 mg in healthy male subjects on evoked pain tests and CNS using PainCart and NeuroCart test batteries. | Explorative, randomized, double-blind, placebo-controlled, 3-way cross-over study to assess the effects of oral cannabidiol 160 and 1500 mg in healthy male subjects on evoked pain tests and CNS using PainCart and NeuroCart test batteries. - Cannabidiol, PainCart & NeuroCart | NL-OMON49760 |
| Initial study of the effects of cannabidiol in patients with generalized anxiety compared to the effects of an anxiolytic (clonazepan) | Pilot study of the effects of Cannabidiol in patients with Generalized Anxiety Disorder compared to the effects of Clonazepan | RBR-2fw8kg |
| Burnout and Distress preventiOn With caNnabidiol in Front-line Health Care workerS deAling wIth COVID-19 | Burnout and Distress preventiOn With caNnabidiol in Front-line Health Care workerS deAling (Bonsai Study) wIth COVID-19: a Randomised Controlled Trial | NCT04504877 |
| Can-ArtEffect and safety of using Canabis derivatives for the treatment of pain in patients with inflammatory Arthritis, such as reumatoid arthritis and ankylosing spondylitis, the latter being a type of arthritis that causes a long term inflammation of the joints of the spine. A randomized, double blinded, placebo controlled trial, i.e. in this drug trial, a control group is given a placebo while another group is given the Cannabis derivative being studied. | CAN-ARTThe efficacy and safety of using cannabis derivatives cannabidiol (CBD) and tetrahydrocannabinol (THC)for the treatment of pain in patients with inflammatory arthritis (RA, AS).A randomized, double blinded, placebo controlled trial - Can-Art | EUCTR2017-004226-15-DK |
| Cannabidiol as a Treatment for PTSD and PTSD Comorbid With TBI | Cannabidiol for Treating PTSD Symptoms and Neurocognitive Impairment in PTSD and PTSD Comorbid With TBI: A Placebo-controlled RCT With Neural-circuit Centered Precision Medicine Prediction of Response. | NCT04550377 |
| Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures | An Open-label, Single-arm Study to Assess the Safety, Pharmacokinetics, and Efficacy of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Participants With Tuberous Sclerosis Complex (Age 1 Month to < 2 Years of Age), Dravet Syndrome (1 Year to < 2 Years of Age), or Lennox-Gastaut Syndrome (1 Year to < 2 Years of Age) Who Experience Inadequately-controlled Seizures | NCT04485104 |
| RCT of CBD for Anxiety in Advanced Breast Cancer | Randomized, Double-blind Phase II Study of a Single Dose of Cannabidiol (CBD) for Acute Anticipatory Anxiety in Advanced Breast Cancer | NCT04482244 |
| CANnabiDiol for CoviD-19 pATiEnts With Mild to Moderate Symptoms | Cannabidiol (CBD) in Patients With Mild to Moderate Symptoms of Coronavirus 2019: A Randomized, Double-blind, Placebo-controlled Clinical Trial | NCT04467918 |
| Cannabidiol 133mg + Cannabigerol 66mg + Tetrahydrocannabinol 4mg Vs Placebo As Adjuvant Treatment in Chronic Migraine - | Randomized, Double Blind Clinical Trial to Study the Effect of Cannabidiol (CBD) 133mg + Cannabigerol (CBG) 66mg + Tetrahydrocannabinol (THC) 4mg a Day As Adjunctive Therapy in the Treatment of Chronic Migraine - CAMTREA TRIAL | NCT04989413 |
| Effect of Non-psychoactive Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm | Effect of Non-psychoactive Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm - a Prospective Double-masked Cross-over Study | NCT04423341 |
| A Study to Assess the Effect of Cannabidiol Oil on Pain After Ureteroscopy for Kidney Stones | Effect of Cannabidiol Oil on Postoperative Pain After Ureteroscopy for Urinary Calculi | NCT04387617 |
| Cannabidiol and Oral Contraceptive Pills: Exploring a Drug-Drug Interaction | Cannabidiol and Oral Contraceptive Pills: Exploring a Drug-Drug Interaction | NCT04396730 |
| Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis | Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis: Understanding the Mechanism and Mediators of Action | NCT04411225 |
| Effect of Local Cannabidiol on Clinical and Inflammatory Outcomes in Periodontal Maintenance Patients. | Effect of Local Cannabidiol on Clinical and Inflammatory Outcomes in Periodontal Maintenance Patients. | NCT05646459 |
| The CBD-IC Randomized Controlled Trial: Evaluation of Hemp Cannabidiol SuppositoRies for Pain and Urinary SymptOms in INterstitial Cystitis (CHRONIC) | The CBD-IC Randomized Controlled Trial: Evaluation of Hemp Cannabidiol SuppositoRies for Pain and Urinary SymptOms in INterstitial Cystitis (CHRONIC) | NCT04349930 |
| The effect of cannabidiol (CBD) on exercise physiology and bioenergetics | A randomised, double-blind, placebo-controlled crossover phase IIa pilot trial exploring the effect of purified oral cannabidiol (CBD) on exercise physiology and bioenergetics in healthy, endurance-trained individuals | ACTRN12620000941965 |
| Cannabidiol in Treatment of Pain due to Attrition of the Knee Joint | Efficacy of Cannabidiol in Treatment of Pain due to symptomatic Osteoarthritis of the Knee: A randomized, double-blind, placebo-controlled - Efficacy of Cannabidiol in Knee Osteoarthritis | EUCTR2019-003591-40-AT |
| Cannabidiol for Prevention of Chemotherapy-induced Peripheral Neuropathy | A Phase II Trial of Cannabidiol for Prevention of Chemotherapy-induced Peripheral Neuropathy in Patients Receiving Oxaliplatin or Paclitaxel Based Chemotherapy | NCT04582591 |
| Does Cannabidiol Attenuate the Acute Effects of ?9-tetrahydrocannabinol Intoxication in Individuals Diagnosed With Schizophrenia? A Double-blind, Randomised, Placebo-controlled Experimental Study | Does Cannabidiol Attenuate the Acute Effects of ?9-tetrahydrocannabinol Intoxication in Individuals Diagnosed With Schizophrenia? A Double-blind, Randomised, Placebo-controlled Experimental Study | NCT04605393 |
| Cannabidiol for At Risk for psychosis Youth | The effect of Cannabidiol on positive psychotic symptoms in At Risk for psychosis Youth: A randomised controlled trial | ACTRN12621000349842 |
| Evaluation of the Effectiveness of Cannabidiol in Treating Severe Behavioural Problems in Children and Adolescents With Intellectual Disability | A Randomized Placebo-controlled Trial of Cannabidiol to Treat Severe Behavioral Problems in Children and Adolescents With Intellectual Disability | NCT04821856 |
| Cannabidiol Bioavailability Trial With Oral Multiple Dose Administration | Characterisation of Relative Bioavailability of GLA-015 in Comparison With an Oily Cannabidiol Solution (NRF 22.10) - a Multiple Dose, Randomised, 2-period Crossover-trial With Twice Daily Administration in Healthy Adult Male and Female Subjects | NCT04790136 |
| Effects of cannabidiol rich cannabis extract on disease severity and quality of life in parkinson disease | Effects of cannabidiol rich cannabis extract on disease severity and quality of life in parkinson disease | TCTR20210303005 |
| Sex Differences in Neural Response to Cannabidiol | Sex Differences in Neural Response to Cannabidiol | NCT04777643 |
| CBD for Chronic Radicular Pain on Chronic Opioid Therapy (COT) | A Phase I/II, Randomized, Double-blind, Placebo-controlled, Single-center Study of the Effects of Cannabidiol (CBD) on Opioid Plasma Levels in Participants With Chronic Radiculopathic Pain Syndromes Maintained on Chronic Opioid Therapy (COT) | NCT04760613 |
| Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias | Phase 2 Trial of Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias | NCT04754399 |
| Cannabidiol for Bilateral Total Knee Arthroplasty | Effects of Cannabidiol (CBD) Oral Solution in Patients Undergoing Bilateral Total Knee Arthroplasty: a Randomized, Controlled, Parallel, Triple Blind, Pilot Study | NCT04749628 |
| Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum Disorder | An Exploratory, Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum Disorder | NCT04745026 |
| Cannabidiol Treatment for Severe and Critical Coronavirus (COVID-19) Pulmonary Infection | Cannabidiol Treatment for Severe and Critical COVID-19 Pulmonary Infection | NCT04731116 |
| Effects of Cannabidiol on recovery after strenuous strength and endurance training. | Effects of Cannabidiol on recovery after strenuous strength and endurance training. - ECRASSET | DRKS00023825 |
| Use of CBD Oil in the Treatment of Panic Attack-Related Fear | Effects of Cannabidiol (CBD) on Reconsolidation Disruption of Pathological Interoceptive Aversive Memory in Humans. | NCT04726475 |
| Cannabidiol and Autonomic Function at Rest | Cannabidiol and Autonomic Function in Individuals at Rest | NCT04731779 |
| Evaluation of the efficacy and safety of medicinal cannabis in children with autism | Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: randomized, double-blind and controlled placebo clinical trial | RBR-5wr2cqq |
| Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors | Study to Evaluate the Efficacy and Safety of CardiolRx™ in Patients With COVID-19 and Cardiovascular Disease or Risk Factors A Double-blind, Placebo-controlled Trial | NCT04615949 |
| The Efficacy and Safety of 3% Cannabidiol (CBD) Cream in Patients With Epidermolysis Bullosa: A Phase II/III Trial | The Efficacy and Safety of 3% Cannabidiol (CBD) Cream in Patients With Epidermolysis Bullosa: A Phase II/III Trial | NCT04613102 |
| Efficacy of Cannabidiol in Knee Osteoarthritis | Efficacy of Cannabidiol in Treatment of Pain Due to Symptomatic Osteoarthritis of the Knee: A Randomized, Double-blind, Placebo-controlled Clinical Trial | NCT04607603 |
| Cannabidiol and CES1 Interactions in Healthy Subjects | An Assessment of the Drug Interaction Potential Between Oral Cannabidiol (Epidiolex®) and the CES1 Substrate Methylphenidate in Healthy Volunteers | NCT04603391 |
| The Effects of Cannabidiol on the Driving Ability of Healthy Adults | The Effects of Cannabidiol on the Driving Ability of Healthy Adults: a Clinical Trial | NCT04590495 |
| Cannabidiol in Opioid Use Disorder and Chronic Pain | Cannabidiol Pharmacotherapy for Co-occurring Opioid Use Disorder and Chronic Pain | NCT04587791 |
| Evaluation of Cannabidiol effect in treatment of patients with Obsessive-Compulsive Disorder | Evaluation of Cannabidiol effect as adjunctive therapy on symptoms of patients with Obsessive-Compulsive Disorder | IRCT20210310050660N1 |
| Analgesic Effects of Cannabidiol for Simple Tooth Extractions in Dental Patients | Surgery With Alternative Pain Management (SWAP): Analgesic Effects of Cannabidiol for Simple Tooth Extractions in Dental Patients | NCT04271917 |
| An Open-label Extension Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome | An Open-label Extension Trial to Investigate the Long-term Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome | NCT04252586 |
| Cannabidiol in refractory childhood epilepsy, a personalized high-quality approach | Cannabidiol in refractory childhood epilepsy, a personalized high-quality approach | CTIS2023-507843-12-01 |
| A Randomised Controlled Trial of Cannabidiol (CBD) for the treatment of Cannabis Use Disorder (CUD) | A Randomised Controlled Trial of Cannabidiol (CBD) for the treatment of Cannabis Use Disorder (CUD) | ACTRN12623000526673 |
| A Double-Blind, Placebo-Controlled, Randomized, Single-Center, Cross-Over Study to Investigate the Pharmacodynamic, Pharmacokinetic, Safety, and Tolerability Profiles of Padsevonil in Healthy Study Participants Receiving Either Ethanol or Cannabidiol. | A Double-Blind, Placebo-Controlled, Randomized, Single-Center, Cross-Over Study to Investigate the Pharmacodynamic, Pharmacokinetic, Safety, and Tolerability Profiles of Padsevonil in Healthy Study Participants Receiving Either Ethanol or Cannabidiol. - Padsevonil interaction study with ethanol or cannabidiol | NL-OMON49954 |
| Cannabidiol for treatment of psychosis and cannabis use | Cannabidiol for treatment of non-affective psychosis and cannabis use | EUCTR2018-004893-84-DK |
| Clinical Study of Synthetic Cannabidiol in Children and Adolescents with 22q11.2 Deletion Syndrome | An Open-Label, Tolerability and Efficacy Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents with 22q11.2 Deletion Syndrome | ACTRN12619000673145 |
| Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia | Pharmacodynamics, Pharmacogenetics, Clinical Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia | NCT03941288 |
| Cannabidiol for Alcohol Use Disorder | A Pilot Human Laboratory Study of Cannabidiol in Alcohol Use Disorder | NCT03904849 |
| Investigation of Cannabidiol for Reduction of NeuroInflammation in Chronic Back Pain | Investigation of Cannabidiol for Reduction of NeuroInflammation | NCT03891264 |
| This Research Study Examines the Effects of Cannabidiol-infused Candy on Reducing the Bacteria Causing Tooth Decay, When Comparing it to a Sugar Free Candy on Adults. | The Antimicrobial Impact of CBD-infused Lozenges on Streptococcus Mutans When Compared to Sugar Free Candy, on Thirty Adults Who Meet the Inclusion Criteria, Randomly Placed Into Two Groups Utilizing Quantitative Polymerized Chain Reaction Bacterial Analysis Technique. | NCT06301113 |
| Assessing the Effects of a Cannabidiol Derived From Hemp Supplement in Healthy Adults | A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Physiological, Biochemical, and Psychometric Impacts of a Brand-Specific Hemp-Derived Cannabidiol Product in Healthy Adults | NCT05212402 |
| Cannabidiol (CBD) treatment for insomnia | Cannabidiol (CBD) treatment for insomnia: a three-week randomised controlled pilot trial | ACTRN12620000070932 |
| A Phase III Double-Blind, Randomised Placebo-Controlled Clinical Trial to evaluate the efficacy and safety of a botanical cannabidiol (CBD) for sleep disturbances in a healthy population. | A Phase III Double-Blind, Randomised Placebo-Controlled Clinical Trial to evaluate the efficacy and safety of a botanical CBD for sleep disturbances in a healthy population via the PROMIS sleep disturbance instrument. | ACTRN12621000632897 |
| An open label extension study to investigate the safety of cannabidiol (GWP42003-P; CBD) in children and adults with inadequately controlled Dravet or Lennox-Gastaut Syndromes | An open label extension study to investigate the safety of cannabidiol (GWP42003-P; CBD) in children and adults with inadequately controlled Dravet or Lennox-Gastaut Syndromes - GWEP1415 | NL-OMON45127 |
| A Clinical Trial on the Antipsychotic Properties of Cannabidiol | A Placebo-Controlled Randomized Cross-Over Clinical Trial on the Antipsychotic Properties of the Endocannabinoid Modulator Cannabidiol | NCT00309413 |
| Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia | Cannabinoid Receptor Antagonist Treatment of Cognitive Dysfunction in Schizophrenia | NCT00588731 |
| Evaluation of the Antipsychotic Efficacy of Cannabidiol in Acute Schizophrenic Psychosis | Evaluation of the Antipsychotic Efficacy of the Phytocannabinoid Cannabidiol in Treating Acute Schizophrenic Psychosis. A Double-Blind, Controlled Clinical Trial | NCT00628290 |
| Cannabidiol for Inflammatory Bowel Disease | Use of Cannabidiol for the Treatment of Inflammatory Bowel Disease | NCT01037322 |
| A study to asses the effects of cannabidiol (CBD) on liver fat levels with people who have fatty liver disease | A randomised, partially-blind, placebo-controlled, pilot, dose-ranging study to assess the effect of cannabidiol (CBD) on liver fat levels in subjects with fatty liver disease. | EUCTR2009-017080-41-GB |
| A Phase 2a Study to Evaluate the Safety and Efficacy of Cannabidiol Only as Maintenance Therapy and Steroid Sparing in Patients With Stable Autoimmune Hepatitis | A Phase 2a Open Label, Single Arm Study to Evaluate the Safety and Efficacy of Cannabidiol Only as Maintenance Therapy and Steroid Sparing in Patients With Stable Autoimmune Hepatitis | NCT04129489 |
| Cannabidiol as an Add-on Treatment to substance abuse in juvenile patients with PSYchosis: a double-blind randomized placebo-controlled study. | Cannabidiol as an Add-on Treatment to substance abuse in juvenile patients with PSYchosis: a double-blind randomized placebo-controlled study. - CAT-PSY | CTIS2024-514393-44-00 |
| Cannabidiol for Anxiety | Prospective Evaluation of Cannabidiol (CBD) on Anxiety: A Pilot Study | NCT04267679 |
| CBD (Cannabidiol)/THC (Tetrahydrocannabinol) Solution as a Pharmacological Strategy for Patients With Fibromyalgia (FibroCann) | CBD/THC Solution as a Pharmacological Strategy for Patients With Fibromyalgia. Single-center, Double-blind, Randomized, Placebo-controlled Clinical Trial Protocol (FibroCann) | NCT05283161 |
| Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer. | Why Antiprogestrone (Mifepristone) and Cyp 26 Inhibitor Must be Combined With Tamoxifen or ( Tamoxifen and Retinoic Acid) for Treating Early Breast Cancer | NCT05016349 |
| CANnabidiol for Parkinson’s Disease Psychosis | CANnabidiol for Parkinson’s Disease Psychosis - CAN-PDP | EUCTR2019-003623-37-GB |
| CANnabidiol for Behavioural Symptoms in Alzheimer’s Disease | CANnabidiol for Behavioural Symptoms in Alzheimer’s Disease - CANBiS-AD | EUCTR2019-002106-52-GB |
| Low Dose of Cannabidiol (CBD) to Treat Mild to Moderate Musculoskeletal Pain | A Controlled-Dose Study Using A One Time Low Dose Cannabidiol Tablet For The Treatment of Mild to Moderate Musculoskeletal Pain | NCT04193631 |
| Cannabidiol Use to Reduce Cravings in Individuals With Opioid Use Disorder on Buprenorphine | A Single-arm, Open-label Feasibility Pilot of Cannabidiol as an Adjunct to Sublingual Buprenorphine on Cue-induced Cravings Among Individuals With Opioid Use Disorder | NCT04192370 |
| The effect of cannabidiol (CBD) on simulated driving performance. | A randomised, double-blinded, crossover trial investigating the dose-dependent effects of purified oral cannabidiol (CBD) on simulated driving performance in healthy volunteers. | ACTRN12619001552178 |
| CBD-Microglia PET Study | Effect of Cannabidiol on Microglial Activation and Central Pain-Sensitization | NCT04398719 |
| Cannabidiol (CBD) for the Treatment of Alcohol Withdrawal | A Randomised Controlled Trial of Cannabidiol (CBD) for the Treatment of Alcohol Withdrawal | NCT04205682 |
| Research on Cognitive Effect of Cannabidiol on Dravet Syndrome and Lennox-Gastaut SyndromeGastaut Syndrome | A Prospective Multi-Center Single-Arm Clinical Trial on Cognitive Effect of Cannabidiol (CBD-OS®) on Dravet Syndrome and Lennox-Gastaut Syndrome | NCT04611438 |
| A Phase 2a Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol as a Steroid-sparing Therapy in Steroid-dependent Crohn's Disease Patients | A Phase 2a, Randomized, Double-blind, Placebo-controlled, Crossover, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol (CBD) as a Steroid-sparing Therapy in Steroid-dependent Crohn's Disease Patients | NCT04056442 |
| Randomised controlled trial to determine the effects of short-term oral cannabidiol (CBD) ingestion on inflammation, muscle damage and functional recovery following downhill running in healthy untrained individuals. | Randomised controlled trial to determine the effects of short-term oral cannabidiol (CBD) ingestion on inflammation, muscle damage and functional recovery following downhill running. | ACTRN12619001120167 |
| A phase II randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of an oral solution of 9-? tetrahydrocannabinol/cannabidiol (THC/CBD) in multiple sclerosis patients with chronic neuropathic pain | A phase II randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of an oral solution of 9-? tetrahydrocannabinol/cannabidiol (THC/CBD) in multiple sclerosis patients with chronic neuropathic pain - BLCL-THC/CBD-01 | CTIS2024-520287-34-01 |
| Mechanisms of CBD for Chronic Pain | Exploring the Mechanisms Underlying the Analgesic Properties of Cannabidiol Using Magnetic Resonance Spectroscopy | NCT04044729 |
| Cannabidiol and vitamin E on blood flow in the brain of older adults | Effectoveness of cannabidiol and vitamin E therapy for improving cerebrovascular function in older adults | ACTRN12626000337370 |
| Modulation of THC Effects by CBD: a Dose-ranging Study | Modulation of ?9-tetrahydrocannabinol Acute Psychoactive Effects by Ranging Doses of Cannabidiol in Healthy, Occasional Cannabis Users: a Controlled, Triple Blind, Randomized, Cross-over Study | NCT06099379 |
| Effects of cannabidiol-enriched cannabis extraction product on cognitive functions and inflammatory markers in Parkinson disease. | Effects of cannabidiol-enriched cannabis extraction product on cognitive functions and inflammatory markers in Parkinson disease. | TCTR20230204001 |
| Treatment of non-motor symptoms of Parkinson's disease with Cannabidiol | Treatment of non-motor symptoms of Parkinson's disease with purified extract of Cannabis sativa | RBR-3tvjjkx |
| Investigation of the potential beneficial effects of cannabidiol in the treatment of tardive dyskinesia | Investigation of the potential beneficial effects of cannabidiol in the management of oral-lingual-buccal dyskinesias using animal studies and a clinical trial | ISRCTN14688109 |
| Effect of cannabidiol in the treatment of crack dependence | Study of the feasibility, safety and short-term results of the therapeutic use of cannabidiol (CBD) in the treatment of cocaine dependence in the form of crack | RBR-4stgs8 |
| The Pharmacokinetics of Single Dose Oral Tetrahydrocannabinol and Cannabidiol | The Pharmacokinetics of Oral Tetrahydrocannabinol and Cannabidiol Across the Spectrum of Glomerular Filtration Rate: a PharmacoKinetic Study | NCT05742724 |
| An open label, study to evaluate the safety of Cannabidiol (CBD) for the prevention of Acute Graft-Versus-Host Disease (GVHD) after allogeneic hematopoietic cell transplantation. | A Phase 2a, open label, multicenter, study to evaluate the pharmacokinetic (PK) profile, safety and efficacy of multiple doses of Cannabidiol (CBD) for the prevention of Acute Graft-Versus-Host Disease (GVHD) after allogeneic hematopoietic cell transplantation (HSCT) | ACTRN12619000623190 |
| A Study of Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy | A Phase 2, Double-blind, Randomized, Placebo-controlled Pharmacokinetic Trial in 2 Parallel Groups to Investigate Possible Drug-drug Interactions Between Stiripentol or Valproate and GWP42003-P in Patients With Epilepsy | NCT02607891 |
| Do cannabidiol and diazepam interact? A proof-of-concept clinical trial. | Does cannabidiol alter the pharmacokinetics and pharmacodynamics of diazepam? A proof-of-concept clinical trial in healthy adults. | ACTRN12624001021561 |
| Randomized, double-blind, Placebo-controlled, 2x2 cross over study assessing the efficacy and safety of cANnabidiol oral solution for joint pain of adjuvant enDOcrine theRApy in patients with early breast cancer | Randomized, double-blind, Placebo-controlled, 2x2 cross over study assessing the efficacy and safety of cANnabidiol oral solution for joint pain of adjuvant enDOcrine theRApy in patients with early breast cancer (PANDORA) - CSET 2021/3373 | CTIS2023-505380-36-01 |
| Randomized, double-blind, Placebo-controlled, 2x2 cross over study assessing the efficacy and safety of cANnabidiol oral solution for joint pain of adjuvant enDOcrine theRApy in patients with early breast cancer | Randomized, double-blind, Placebo-controlled, 2x2 cross over study assessing the efficacy and safety of cANnabidiol oral solution for joint pain of adjuvant enDOcrine theRApy in patients with early breast cancer (PANDORA) - CSET 2021/3373 | CTIS2023-505380-36-00 |
| Therapy With Paravertebral Oxygen-ozone Injections and Topical Cannabidiol and ß-Caryophyllene Patch in Neck Pain | Effectiveness of a Combined Therapy With Paravertebral Oxygen-ozone Injections and Topical Patch Containing Cannabidiol and ß-Caryophyllene for Treatment of Neck Pain: a Prospective, Randomized, Controlled Trial. | NCT06099171 |
| Bioequivalence Assessment of Oral Administration Vs. Oral Spray of a Cannabinoids (Tetrahydrocannabinol and Cannabidiol) | Bioequivalence Assessment of Oral Administration Vs. Oral Spray of a Cannabinoid Combination (?9 -Tetrahydrocannabinol (THC) and Cannabidiol (CBD) In 1:1 Ratio) | NCT01893424 |
